Predict your next investment

Corporation
HEALTHCARE | Biotechnology
mirnarx.com

See what CB Insights has to offer

Founded Year

2007

Stage

IPO | IPO

Total Raised

$96.1M

Date of IPO

10/1/2015

Market Cap

0.17B

Stock Price

2.42

About Mirna Therapeutics

Mirna Therapeutics is a biotechnology research and development company that focuses on miRNA-directed oncology therapies.

Mirna Therapeutics Headquarter Location

2150 Woodward Street Suite 100

Austin, Texas, 78744,

United States

512-901-0900

Latest Mirna Therapeutics News

The World's First-in-class MiRNA Therapeutics To Cure Diabetes By Pancreatic Beta Cell Regeneration

May 7, 2021

The World's First-in-class MiRNA Therapeutics To Cure Diabetes By Pancreatic Beta Cell Regeneration RNA therapeutics, a breakthrough for major modern diseases such as Corona 19, orphan diseases, and chronic diseases Author: May 6, 2021 7:00 PM EDT SEOUL, South Korea, May 7, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), has selected its first technological investment target to expand its new bio business. Nexturn Bio announced that it has secured a 50% stake in RosVivo Therapeutics, Inc. as its final investment destination under support from its parent company Nexturn Bioscience Co., Ltd. RosVivo, planned to receive investment from Nexturn Bio  Inc., is an R&D company for miRNA (MicroRNA) new drugs in Nevada. While the development of RNA vaccines has been spotlighted since the Corona-19 outbreak, RSVI-301, a new drug pipeline of RosVivo targeting diabetes, also uses miRNA (micro RNA). Consisting of 20-24 nucleotide, miRNA is known as a "small cleaner" in the body that naturally regulates metabolic processes of genes and proteins. Since these miRNA treatments inject human-derived genetic materials, they are expected to be of greater value in stability than conventional mRNA treatments using external genetic materials like viruses. In particular, miR- 10-5p study, underlying study of the new drug development, enables the researchers to observe the world's first pancreatic beta cell regeneration. Nexturn Bio  Inc. and RosVivo Therapeutics, Inc. said they will appoint Scientific Advisory Board (SAB) for thorough verification as it is important precedent for diabetes research. The advisors will be staffed at several major national Hospitals, such as Stanford University of Medicin e, to support professional advice throughout the drug development. Nexturn Bio Inc. plans to catch both "innovation" and "marketability" through RosVivo's new miRNA drug. It has been reported that CEO Song Myung-Seok participated to discover candidates while establishing a subsidiary. "RosVivo is the first official investment of Nexturn Bio, and RSVI-301 of RosVivo will be an innovative opportunity to open a new era of medicine after mRNA and challenge the complete cure of diabetes," said the CEO. View original content to download multimedia: http://www.prnewswire.com/news-releases/the-worlds-first-in-class-mirna-therapeutics-to-cure-diabetes-by-pancreatic-beta-cell-regeneration-301282932.html SOURCE NEXTURN Bio Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Mirna Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Mirna Therapeutics in 1 CB Insights research brief, most recently on Jan 23, 2019.

Expert Collections containing Mirna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mirna Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mirna Therapeutics Patents

Mirna Therapeutics has filed 20 patents.

The 3 most popular patent topics include:

  • Angiology
  • Biotechnology
  • Diseases of the eye and adnexa
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/11/2015

4/4/2017

MicroRNA, RNA, RNA interference, Molecular biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/11/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/4/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

MicroRNA, RNA, RNA interference, Molecular biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.